febit group reported a strategic investment and technology development agreement with In-Q-Tel, which will facilitate further development of the company’s Geniom® Technology to detect pathogens.
The technology development agreement with In-Q-Tel is anticipated to improve the sensitive, flexible, and fully automated Geniom platform for the multiplexed detection and classification of known and unknown pathogens for the special needs of biosecurity, according to the companies.
“The scope of this agreement will address the current needs of the biosecurity industry, as well as provide value to the other aspects of our business,” said Anthony P. Caruso, vp of informatics at febit and head of febit’s bio security activities. “Our overall objective is to further increase the sensitivity of the Geniom instruments, and to enhance our ability to quickly identify the presence of thousands of unique organisms in a single assay, all with the Geniom’s inherent ability to adapt to newly discovered samples in a matter of hours.”
In-Q-Tel is the strategic, not-for-profit investment firm that works to identify, adapt, and deliver innovative technology solutions to support the mission of the U.S. intelligence community. Launched by the CIA in 1999 as a private, independent organization, In-Q-Tel’s mission is to identify and partner with companies developing cutting-edge technologies that serve the national security interests of the U.S.